Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
38 results about "Protein-tyrosine kinase activity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Substituted quinoline compounds and methods of use
ActiveUS20120219522A1Growth inhibitionBiocideOrganic chemistryKinase activityProtein-Tyrosine Kinases
The present invention provides novel substituted quinoline compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:SUNSHINE LAKE PHARM CO LTD
Kinase inhibitors and uses thereof
InactiveUS20080255155A1Promote motilityPromote invasionBiocideOrganic chemistryKinase activityProtein-Tyrosine Kinases
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds, compositions and methods for the inhibition of kinase activity. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions.
Owner:METHYLGENE
Inhibitors of protein tyrosine kinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:METHYLGENE
Inhibitors of Protein Tyrosine Kinase Activity
Owner:METHYLGENE
Inhibitors of Protein Tyrosine Kinase Activity
InactiveUS20130096136A1Inhibit angiogenesisInhibit tyrosine kinase activityBiocideOrganic chemistryDiseaseKinase activity
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
Owner:METHYLGENE
Inhibitors of protein tyrosine kinase activity
ActiveUS20090264440A1Promote motilityPromote invasionBiocideSenses disorderKinase activityProtein-Tyrosine Kinases
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Inhibitors of protein tyrosine kinase activity
InactiveUS20110077240A1Inhibit angiogenesisInhibit tyrosine kinase activityBiocideSenses disorderDiseaseKinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
Owner:METHYLGENE
Substituted pyrazolone compounds and methods of use
The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:BEIJING FINDCURE BIOSCIENCES LTD
Substituted quinoline compounds and methods of use
Owner:SUNSHINE LAKE PHARM CO LTD
Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors
ActiveUS8198301B2Improve anti-tumor effectUnique structureBiocideOrganic chemistryQuinolineQuinazoline
A compound of formula (I),a pharmaceutically acceptable salt, or hydrate thereof, and a method of preparing the same. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal comprising administering to said mammal a pharmaceutical composition comprising a compound of formula (I).
Owner:TIANJIN HEMAY ONCOLOGY PHARMA CO LTD
Substituted quinoline compounds and methods of use
Owner:SUNSHINE LAKE PHARM CO LTD
Selected inhibitors of protein tyrosine kinase activity
Owner:METHYLGENE
Substituted pyrazolone compounds and methods of use
The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:BEIJING FINDCURE BIOSCIENCES LTD
Application of brazilin in preparation of drugs
ActiveCN104173328APrevent proliferationInhibit migrationOrganic active ingredientsSenses disorderDiseaseProtein-Tyrosine Kinases
The invention discloses application of brazilin in preparation of products for prevention, mitigation and / or treatment of diseases related to protein tyrosine kinase activity abnormal increase and vascular proliferation. Brazilin has the effects of inhibiting protein tyrosine kinase (PTKs) activity and inhibiting proliferation and migration of the rat thoracic aortic vascular smooth muscle cell (VSMC). Brazilin can prevent, mitigate and / or treat PTKs activity abnormal increase related diseases like tumors, restenosis after percutaneous coronary intervention (PCI), atherosclerosis, high blood pressure, multiple sclerosis, diabetic retinopathy, endometriosis, psoriasis and other skin diseases, asthma and other diseases. Brazilin can prevent, mitigate and / or treat vascular proliferation related diseases like restenosis after PCI, atherosclerosis, high blood pressure, neointima formation after vascular transplantation, vascular diseases after organ transplantation, diabetic angiopathies and the like.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Aminoquinazoline derivatives and their salts and methods of use thereof
ActiveUS20160039838A1Reduce severityHeavy metal active ingredientsSenses disorderDiseaseKinase activity
Provided herein are aminoquinazoline compounds, salts and uses thereof. The compounds have Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Also provided herein are pharmaceutical compositions containing the compounds disclosed herein, and uses of the compounds or the compositions for preventing, managing, treating or lessening the severity of a proliferative disorder in a patient and for modulating the protein tyrosine kinase activity.
Owner:SUNSHINE LAKE PHARM CO LTD
Inhibitors of Protein Tyrosine Kinase Activity
InactiveUS20130096088A1Inhibit angiogenesisInhibit tyrosine kinase activityBiocideSenses disorderDiseaseKinase activity
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
Owner:METHYLGENE
Substituted pyrazolone compounds and methods of use
The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:BEIJING FINDCURE BIOSCIENCES LTD
Methods of preparing and using quinazoline and quinoline derivatives
InactiveUS20120225872A1Improve anti-tumor effectUnique structureBiocideOrganic chemistryCancer cellMedicine
A method of preparing a compound of formula (I),A method for treating cancer or inhibiting growth of cancer cells including administering to a patient mammal in need thereof a pharmaceutical preparation including the compound. A method of treating or preventing a physiological disorder caused by abnormal protein tyrosine kinase activity in a mammal including administering to a mammal a pharmaceutical preparation including the compound.
Owner:TIANJIN HEMAY ONCOLOGY PHARMA CO LTD
Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
ActiveUS20190152954A1EGFR kinase inhibitory activityHigh selectivityOrganic active ingredientsOrganic chemistryImmunologic disordersDisease
An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and / or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
Owner:SHENZHEN TARGETRX INC
Inhibitors of protein tyrosine kinase activity
Owner:METHYLGENE
Methods and compositions for detecting and modulating cancer cells
InactiveUS20170168056A1Prevent and ameliorate resistanceEnhance the anti-tumoral efficacy of the microtubule binding agentNervous disorderMicrobiological testing/measurementCancer cellProtein-Tyrosine Kinases
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV +1
Methods and compositions for detecting and modulating cancer cells
InactiveCN108883171ANervous disorderMicrobiological testing/measurementCancer cellProtein-Tyrosine Kinases
Owner:MASSACHUSETTS INST OF TECH
Substituted pyrazolone compounds and methods of use
The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:BEIJING FINDCURE BIOSCIENCES LTD
Inhibitors of Protein Tyrosine Kinase Activity
The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.
Owner:METHYLGENE
Inhibitors of protein tyrosine kinase activity
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Owner:MIRATI THERAPEUTICS INC
Substituted pyrazolone compounds and methods of use
The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Owner:BEIJING FINDCURE BIOSCIENCES LTD
Aminopyrimidines for inhibiting protein tyrosine kinase activity
ActiveCN108137544BPreserve or increase kinase activityIncreased or decreased kinase activityOrganic active ingredientsOrganic chemistryImmunologic disordersDisease
The present invention relates to aminopyrimidine compounds with inhibitory effect on protein tyrosine kinase activity, as well as their preparation and application. Specifically, the invention discloses an aminopyrimidine compound represented by formula (I) and the compound, its pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, crystal form, prodrug or isotope Variant pharmaceutical compositions. The compounds of the present invention can be used to treat and / or prevent protein tyrosine kinase related diseases, such as cell proliferative diseases, cancer, immune diseases.
Owner:SHENZHEN TARGETRX INC
Anti-proliferative composition
InactiveCN1615155BStrong antiproliferative activityAntiproliferative activity fullyHydrocarbon active ingredientsHydroxy compound active ingredientsApigeninProtein-Tyrosine Kinases
Non-estrogen-dependent hyperproliferation of cells in animals or humans can be prevented or treated by means of a pharmaceutical or nutritional composition containing a combination of at least three components from: a) two or more inhibitors of the G1 / S phase of the cell cycle; and b) two or more inhibitors of the G2 / M phase of the cell cycle; and c) two or more inhibitors of protein tyrosine kinase activity. Especially, component a) comprises two or more compounds selected from flavanolignans, carotenoids and isoflavone; component b) comprises two or more compounds selected from flavanolignans, hydroxylated stilbenes, isoflavones and apigenin; and component c) comprises two or more compounds selected from flavanolignans and isoflavones.
Owner:NV NUTRICIA
Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
ActiveUS11111233B2High selectivityHigh activityOrganic active ingredientsOrganic chemistryDiseaseProtein-Tyrosine Kinases
An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and / or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.
Owner:SHENZHEN TARGETRX INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com